Immutep (ASX:IMM) said its Phase II EFTISARC-NEO trial evaluating the therapy of the company's drug candidate eftilagimod alfa, in combination with prescription medicine Keytruda and radiotherapy as treatment for patients with resectable soft tissue sarcoma (STS), showed an increase in tumor fibrosis rate, according to a Monday filing with the Australian bourse.
The trial showed that the combination therapy exceeded the median tumor fibrosis rate of 35% compared to the historical median of 15% observed with radiotherapy alone, meeting the trial's primary endpoint, the filing said.
Tumor fibrosis is linked to improved overall and recurrence-free survival in patients with STS.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.